New pill could take the edge off social anxiety on the spot
NCT ID NCT06510504
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a single dose of BNC210 can quickly reduce anxiety in people with social anxiety disorder. 370 adults took either the drug or a placebo before a public speaking challenge and rated their distress. The goal is to see if BNC210 works as an as-needed treatment for social anxiety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNC210
What this could lead to
If successful, BNC210 could offer a fast-acting, on-demand option to ease anxiety during social situations like public speaking.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AFFIRM-1 Study Site
Encino, California, 91316, United States
-
AFFIRM-1 Study Site
La Jolla, California, 92037, United States
-
AFFIRM-1 Study Site
Los Angeles, California, 90025, United States
-
AFFIRM-1 Study Site
Oceanside, California, 92056, United States
-
AFFIRM-1 Study Site
San Diego, California, 92103, United States
-
AFFIRM-1 Study Site
San Jose, California, 95124, United States
-
AFFIRM-1 Study Site
Sherman Oaks, California, 91403, United States
-
AFFIRM-1 Study Site
Temecula, California, 92591, United States
-
AFFIRM-1 Study Site
Jacksonville, Florida, 32256, United States
-
AFFIRM-1 Study Site
Lauderhill, Florida, 33319, United States
-
AFFIRM-1 Study Site
Miami Lakes, Florida, 33016, United States
-
AFFIRM-1 Study Site
Orlando, Florida, 32801, United States
-
AFFIRM-1 Study Site
Tampa, Florida, 33607, United States
-
AFFIRM-1 Study Site
Decatur, Georgia, 30030, United States
-
AFFIRM-1 Study Site
Boston, Massachusetts, 02114, United States
-
AFFIRM-1 Study Site
Boston, Massachusetts, 02131, United States
-
AFFIRM-1 Study Site
Princeton, New Jersey, 08540, United States
-
AFFIRM-1 Study Site
Brooklyn, New York, 11229, United States
-
AFFIRM-1 Study Site
Charlotte, North Carolina, 28211, United States
-
AFFIRM-1 Study Site
Media, Pennsylvania, 19063, United States
-
AFFIRM-1 Study Site
Austin, Texas, 78737, United States